Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses

Jegaskanda, Sinthujan; Vandenberg, Kirsten; Laurie, Karen; Loh, Liyen; Kramski, Marit; Winnall, Wendy Rachael; Kedzierska, Katherine; Rockman, Steven; Kent, Stephen J.

doi:10.1093/infdis/jiu334

Cited by 59 publications

(68 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been renewed interest in the nonneutralizing functions of Abs during clinically important human infections, such as those involving HIV (37-41), dengue (42), and influenza viruses (24)(25)(26)(27)(28)(29)(30). In both animal models and mild-to-moderate human influenza infections, Fc-FcγR interactions aid in the clearance of influenza infection (24)(25)(26)(27)(28)(29)(30).…”

Section: Discussionmentioning

confidence: 99%

“…In both animal models and mild-to-moderate human influenza infections, Fc-FcγR interactions aid in the clearance of influenza infection (24)(25)(26)(27)(28)(29)(30). Herein, we performed the first comprehensive investigation to our knowledge of the Fc functional Ab response in serial samples across two cohorts of subjects hospitalized with severe H7N9 or seasonal influenza infections.…”

Section: Discussionmentioning

confidence: 99%

“…There is a growing interest in passive transfer of anti-influenza Abs in severe influenza, with some efficacy observed in small human studies (43,44) and animal models (45). Both polyclonal immunoglobulin preparations (28) and some monoclonal Abs can have significant Fc-mediated functions across a range of influenza strains (24,25,33). Future interventional studies complementing anti-influenza ADCC in subjects with severe influenza are warranted.…”

Section: Discussionmentioning

confidence: 99%

“…Nonneutralizing Abs have been shown to assist in the clearance of influenza infections in animal models and may be important in the control of severe influenza infections (24)(25)(26)(27)(28)(29)(30). We first studied serial samples from subjects infected with H7N9 and seasonal influenza using a recently developed recombinant soluble FcγR (rsFcγR) dimer ELISA (31).…”

Section: L I N I C a L M E D I C I N Ementioning

confidence: 99%

“…**P < 0.01, ***P < 0.001. Several mouse studies, macaque studies, and human cohort studies in recent years have implicated ADCC and other Fc-mediated Ab effector mechanisms with control of influenza (24)(25)(26)(27)(28)(29). A recent study suggested that high titers of ADCC-mediating Abs might reduce clinical symptoms and viral replication following an A/Wisconsin/67/131/2005 (H3N2) influenza challenge of humans (30).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Vanderven¹,

Liu²,

Ana-Sosa-Batiz³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: L I N I C a L M E D I C I N Ementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Vanderven¹,

Liu²,

Ana-Sosa-Batiz³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

Cross‐reactive antibody‐dependent cellular cytotoxicity antibodies are increased by recent infection in a household study of influenza transmission

et al. 2019

View full text Add to dashboard Cite

Objectives Influenza causes a spectrum of disease from asymptomatic infection to fatal outcome, and pre‐existing immunity can alter susceptibility and disease severity. In a household transmission study, we recruited outpatients with confirmed influenza virus infection and prospectively identified secondary infections in their household contacts, therefore identifying infection cases with baseline samples for determining immune‐mediated protection from influenza infection. Methods We examined baseline broadly reactive immune correlates of relevance to universal vaccine development, specifically antibody‐dependent cytotoxic (ADCC) antibodies and T‐cell responses in functional assays. Antibodies were assessed in a cell‐based NK cell degranulation assay by flow cytometry, and T‐cell responses were assessed by IFN‐γ intracellular cytokine staining flow cytometry assay. Results The magnitude of antibody responses and ADCC function for multiple influenza‐specific proteins was lower in participants who became infected, consolidating the role of pre‐existing antibodies in protection from seasonal influenza virus infection. Among H1N1‐infected contacts, we found that higher levels of pre‐existing H1‐haemagglutinin ADCC responses correlated with reduced symptom severity. Recent infection boosted the titre and magnitude of haemagglutinin‐, neuraminidase‐ and nucleoprotein‐specific ADCC antibodies. Limited T‐cell samples precluded conclusions on the role of pre‐existing T‐cell responses. Conclusions Overall, ADCC responses are a protective correlate against influenza virus infection that should be considered in future vaccine development and evaluation. Influenza‐specific ADCC responses are elevated in uninfected subjects, associated with reduced symptoms and boosted by recent infection, whilst HA stem and NA IgG are also elevated in uninfected participants irrespective of ADCC function.

show abstract

Administration of intravenous immunoglobulin in the treatment of COVID‐19: A review of available evidence

Moradimajd

Samaee

Maroufi

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Since December 31, 2019, unknown causes of pneumonia have been reported in Wuhan, China. This special pneumonia associated with a novel coronavirus was named 2019-nCoV by the World Health Organization (WHO) in January 2020.From the beginning of this infectious disease, clinicians and researchers have been endeavoring to discover an effective and suitable treatment for affected patients.To date, there is no definitive and specific treatments for coronavirus disease-19 (COVID-19) infection while drugs introduced are still in the clinical trial phase.Intravenous immune globulin (IVIG) is a biological product prepared from the serum and an optional treatment for patients with antibody deficiencies. In many countries, much attention has been paid to the use of IVIG in the treatment of patients with COVID-19. Due to the therapeutic importance of IVIG in virus infections, in the current study, we reviewed the possible effect of IVIG in viral infections and potential evidence of IVIG therapy in patients with COVID-19 virus.

show abstract

Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses

Abstract: IVIG preparations contain broadly cross-reactive ADCC mediating antibodies. IVIG may provide at least some level of protection for individuals at high risk of severe influenza disease, especially during influenza pandemics prior to the development of effective vaccines.

Cited by 59 publications

References 40 publications

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Cross‐reactive antibody‐dependent cellular cytotoxicity antibodies are increased by recent infection in a household study of influenza transmission

Administration of intravenous immunoglobulin in the treatment of COVID‐19: A review of available evidence

Contact Info

Product

Resources

About